New products for pharmacists: Rx, OTC, and generics (February 2012)

February 15, 2012

A survey of new Rx, new generic, and new OTC products

RX CARE

New drugs

FDA has approved Antares' topical oxybutynin gel 3% product for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. The clear, odorless gel is available in a metered-dose pump. Applied once daily to the thigh, abdomen, upper arm, or shoulder, an 84 mg (approximately 3 mL) dose delivers a consistent dose of oxybutynin through the skin over a 24-hour period. Because the active ingredient is delivered transdermally, it is not metabolized by the liver in the same way as orally administered oxybutynin. Under an exclusive licensing agreement, Watson Pharmaceuticals anticipates launching the product this year. ( http://www.watson.com/ / 800-900-1644)

LEO Pharma received approval for Picato (ingenol mebutate) gel (0.015%, 0.05%), a topical therapy for actinic keratosis (AK) that can be used for as little as 2 or 3 days. AKs are precancerous lesions with the potential to progress to squamous cell carcinoma. ( http://www.leo-pharma.us/home/products/LEO-pharma-products.aspx)